Logo

Opko Acquires Curna for $10M

Feb 03, 2011
Premium

Opko Health said this week that it has acquired Curna, an early-stage developer of non-coding RNA-based treatments for cancer, heart disease, metabolic disorders, and genetic anomalies.

Curna's technology, according to Opko, allows for the up-regulation of target proteins and was exclusively licensed from the Scripps Research Institute.

According to a filing with the US Securities and Exchange Commission, Opko acquired all outstanding shares of privately held Curna for $10 million in cash.

Additional terms were not disclosed.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Tools & Technology
RNAi
non-coding RNA
Opko
Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.